ArticleJournal of magnetic resonance imaging : JMRI2026
A Quantitative Modification of VI-RADS for Bladder Cancer at the Ureteral Orifice: A Reader Study on MRI With Varying Experience Levels.
Article in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial for "A Quantitative Modification of VI-RADS for Bladder Cancer at the Ureteral Orifice: A Reader Study on MRI With Varying Experience Levels".Journal of magnetic resonance imaging : JMRI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundWhile the current Vesical Imaging Reporting and Data System (VI-RADS) provides a valuable tool for evaluating bladder cancer, it is not tailored to the ureteral orifices and primarily relies on subjective evaluation. PURPOSE: To identify significant parameters from MRI for diagnosing muscle-invasive bladder cancer (MIBC) at the ureteral orifice, and to evaluate their incremental value to VI-RADS for readers of varying experience. STUDY TYPE: Retrospective. POPULATION: Development cohort: 81 patients with ureteral orifice bladder tumors (mean age, 68 ± 9; 60 men). External validation cohort: 34 patients (mean age, 63 ± 5; 22 men). FIELD STRENGTH/SEQUENCE: 3.0 T; fast spin-echo T2-weighted imaging, single-shot echo planar diffusion-weighted imaging, 3D spoiled gradient echo T1-weighted dynamic contrast-enhanced imaging. ASSESSMENT: Four radiologists of varying experience independently assigned VI-RADS scores. Quantitative parameters (tumor length, tumor contact length [TCL], stalk width [SW], and K STATISTICAL TESTS: Intraclass correlation coefficient, weighted κ analysis, independent samples t-test, Mann-Whitney U test, chi-square test, receiver operating characteristic curve analysis, univariate and multivariate logistic regression, 1000 bootstrap resamples, DeLong's test, and McNemar's test with Bonferroni correction. Significance was defined as p < 0.05, with p < 0.008 for multiple comparisons.
resultsMultivariate analysis identified TCL (odds ratio [OR] = 1.12) and stalk width (OR = 1.74) as independent predictors. In both cohorts, the TCL + SW-modified VI-RADS significantly improved sensitivity over the original VI-RADS for diagnosing MIBC at the ureteral orifice in two junior radiologists. The TCL + SW-modified VI-RADS did not significantly improve sensitivity compared with the TCL-modified VI-RADS in either cohort (p = 0.25-0.50). DATA
conclusionThe integration of TCL and stalk width into the VI-RADS improves diagnostic performance for MIBC at the ureteral orifice, particularly for less-experienced radiologists. Nevertheless, external validation in larger, multicenter cohorts is required. EVIDENCE LEVEL: 3. TECHNICAL EFFICACY: Stage 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.